Methylprednisolone treatment in patients with brain tumors.
A study was made in 10 patients with brain tumors of the effect of methylprednisolone sodium succinate (Solu-Medrol) on clinical neurological status, intracranial pressure, and periventricular elastance. Significant clinical improvement and reduction in periventricular elastance both ocurred within 24 hours of starting treatment, whereas intracranaial pressure was not significantly reduced until the 2nd day of therapy.
D000238:Adenoma, Chromophobe / Q000188:drug therapy*; D000328:Adult; D001932:Brain Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D007427:Intracranial Pressure / Q000187:drug effects; D008775:Methylprednisolone / Q000627:therapeutic use*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011300:Preoperative Care
D008775:Methylprednisolone